



European Charcot Foundation

Co-ordination of Multiple Sclerosis Research in Europe

SYMPOSCIA

PROGRAMME EUROPEAN CHARCOT FOUNDATION SYMPOSIUM 2008

November 13, 14 and 15, 2008
Taormina, Sicily, Italy

Thursday November 13, 2008

11.00 – [Satellite Symposium Novartis](#)
13.00

Chairmen: C. Confavreux, O.R. Hommes

14.00 –	Welcome	O.R. Hommes
14.05		
14.05 –	XIV European Charcot Foundation Lecture	A. Sadovnick
14.50	The natural history of Multiple Sclerosis and Gender	
14.50 –	Discussion	
15.20		
15.20 –	Organisational details	M. Friedrichs
15.25		

Chairmen: A. Sadovnick, D. Wingerchuk Epidemiology

15.25 –	Gender related immuno-inflammatory factors and	G. Candore
15.45	human diseases	
15.45 –	Clustering of Multiple Sclerosis, age of onset and	M. Pugliatti
16.05	gender in Sardinia	
16.05 –	Coffee break	
16.30		
16.30 –	Increasing incidence of Multiple Sclerosis in women in	M. Debouverie
16.50	Lorraine (France)	
16.50 –	Increase of incidence of Multiple Sclerosis in women:	P. S. Sørensen
17.10	data from the Danish Multiple Sclerosis Registry	
17.10 –	Discussion	
17.30		

18.00 – [Satellite Symposium Octapharma](#)
20.00

20.00 – Welcome Reception
21.00

Friday November 14, 2008

Chairmen: R. Gonsette, P. Soelberg Sørensen Epidemiology

08.30 – 08.50	Life style changes and demographic patterns of Multiple Sclerosis	G. Ebers
	Clinical evolution and gender	
08.50 – 09.10	Disease evolution and gender	G. Edan
09.10 – 09.30	Neuromyelitis optica (Devic). What is the role of gender?	D. Wingerchuk
09.30 – 09.50	Discussion	
09.50 – 10.20	Coffee break	
	Chairmen: G. Edan, O. Fernandez	
	Clinical evolution and gender	
10.20 – 10.40	Pregnancy and Multiple Sclerosis	J. Haas
10.40 – 11.00	Leber's disease and gender	J. Palace
11.00 – 11.20	Gender differences in MRI, studies on Multiple Sclerosis	F. Fazekas
11.20 – 11.40	Early onset Multiple Sclerosis. The role of gender	M. Tintoré
11.40 – 12.00	Discussion	
12.00 – 13.30	Lunch	
	Chairmen: M. Clanet, G. Ebers	
	Clinical evolution and Gender	
13.30 – 13.50	Sex hormones, brain damage and clinical course of Multiple Sclerosis.	V. Tomassini
13.50 – 14.10	Sex differences in pro-inflammatory cytokines	J. Eikelenboom
	Genetics	
14.10 – 14.30	Gender-bias in auto-immune diseases. X-chromosome inactivation in women with Multiple Sclerosis	G.P. Knudsen
14.30 – 14.50	Gene expression in relation to gender in Multiple Sclerosis	A. Achiron
14.50 – 15.10	Discussion	
15.10 – 15.40	Coffee break	
	Chairmen: J. Palace, J. Wolinsky	
	Environmental factors and gender	
15.40 – 16.00	Environmental factors in Multiple Sclerosis	S. Cook
16.00 – 16.20	Time of exposure of environmental factors in Multiple Sclerosis	G. Ebers
16.20 – 16.40	Women's life style and Multiple Sclerosis	J. Haas

16.40 –	Manipulation of environment and Multiple Sclerosis	P. Cabre
17.00		
17.00 –	EBV and Multiple Sclerosis	D. Pohl
17.20		
17.20 –	The triggering role of Herpes viridae in Multiple Sclerosis	H. Perron
17.50		
17.50 –	Oral contraceptives and the risk of Multiple Sclerosis	A. Alonso
18.10		
18.10 –	Discussion	
18.30		

Saturday November 15, 2008

Chairmen: G. Comi, R. Voskuhl

Experimental mechanisms

09.00 –	Sexual dimorphism in the white matter of rodents	M. Cergnet
09.20		
09.20 –	Neuro-protective and anti-inflammatory effects of estrogen receptors ligand treatment in mice	S. Tiwari Woodruff
09.40		
09.40 –	White matter plasticity and enhanced remyelination in maternal CNS of mice	C. Gregg
10.00		

Pathology

10.00 –	Gender differences in de- and remyelination in Multiple Sclerosis	T. Kuhlmann
10.20		
10.40 –	Discussion	
11.00		

11.00 – Coffee Break
11.30

11.30 – European Charcot Foundation Young Investigators Awards presentation
12.00

12.00 – Lunch
13.30

Chairmen: F. Fazekas, O.R. Hommes

Treatment

13.30 –	Are there gender effects in disease modifying treatments?	G. Comi
13.50		
13.50 –	Glatiramer Acetate treatment in primary progressive Multiple Sclerosis. Why males appear to respond favourably	J. Wolinsky
14.10		
14.10 –	Estriol treatment in Multiple Sclerosis	R. Voskuhl
14.30		
14.30 –	Vitamin D treatment in Multiple Sclerosis	K.-M. Myhr
14.50		
14.50 –	Post marketing of Disease Modifying Drugs. Gender questions	M. Trojano
15.10		
15.20 –	PopartMUS trial, a child of PRIMIS	C. Confavreux
15.50		
15.50 –	Discussion	
16.10		
16.10 –	Closure	O.R. Hommes
16.15		

